Kornimate/medical-research-clean huggingface dataset:
diagnostic and prognosis value of circulating dna for crc patients' surveillance after curative treatment

Conditions: Colorectal Cancer

Summary: inspite of curative treatment 30-50% patients with colorectal cancer (crc) develop tumor relapse during the first 3 years after treatment of the primary tumor. treatment of relapses is based on surgical resection, when possible, chemotherapy and targeted therapies. to detect recurrences or metastases, a surveillance strategy is recommended for patients able to withstand complementary treatment during a five-year period. over this period, the probability of one false-positive result is 87%. considering that less than 10% of recurrent patients are suitable for potentially curative treatment and that more intensive programs enable an increase of the overall rate of curative resection but do not result in reduced mortality, less time and cost-consuming, tailored follow-up is necessary. the level of circulating ccfdna, defined as extra cellular dna, increases in crc patients. the inplex® method could validate the use of ccfdna as a cancer biomarker in terms of prognosis and surveillance. tubes for ccfdna analysis will be taken during medical examination at the same time of the cea dosage (if it was not made before the consultation). cryotubes of plasma will be sent for analysis in the laboratory inserm (national health institute) of montpellier and the remaining plasma will be kept in biological collection. patients will have a consultation of follow-up every 3-4 months during which the dosage of cea and ccfdna will be realized as well as a medical examination, a general examination (weight, size, and blood pressure), an evaluation of the indices of performance status and a nutritional evaluation in case of loss of weight.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * primary diagnosis of stages ii and iii crc: * is already operated and histological proven (biopsy at least) * is patient that must be operated: curative treatment for stages ii and iii crc * patient benefiting from a program personalized by care * written informed consent exclusion criteria: * patient already treated for stages ii and iii crc and in surveillance * patient with indication or with palliative treatment * pregnant or nursing patients * known pregnancy * difficulties to understand the protocol * patients under protection measure (guardianship, curatorship, protection of justice)

Keywords: colorectal cancer cancerology translational research ccfdna
comparison of vaginal and transdermal oestrogen before frozen thawed embryo transfer

Conditions: Embryo Transfer; Infertility

Summary: the purpose of this study is to compare pregnancy outcomes of frozen-thawed embryo transfer after endometrial preparation with vaginal estradiol or transdermal estradiol and to evaluate women's satisfaction

frozen-thawed transfer embryo are more and more frequent but to date, there is no consensus on the ideal management of the adequate endometrial preparation. artificial preparation of endometrium is commonly used in assisted reproduction center because it is more easy to schedule. estradiol could be administrate by oral, vaginal or transdermal, but no protocol seems to improve clinical pregnancy rates. to investigator's knowledge, transdermal estradiol has never been compare to vaginal administration before frozen-thawed embryo transfer. because transdermal administration could improve satisfaction of patients and reduce duration of treatment (when compare to oral administration), the investigators conduct a prospective study to compare clinical pregnancy rate after transdermal or vaginal estradiol administration to prepare the endometrium before frozen-thawed embryo transfer. the investigator also evaluate side effects and patients satisfaction in both protocol. the patients choose if they prefer vaginal or transdermal protocol after receiving sufficient information during medical consultation.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and \<43 * frozen-thawed embryo transfer after exogenously administered estrogen in either way transdermal or vaginal * patients who accepted being included and signed the consent forms. exclusion criteria: * patient who refuse to participate * frozen-thawed embryotransfer after stimulated or natural cycle * oocyte or sperm donation * endometrial thickness after 21 days \<6mm * non-french speaking patients * women under legal guardianship * women with no health or social security coverage
use of extracellular vesicles (ev) for knee osteoarthrosis

Conditions: Knee Osteoarthrosis

Summary: extracellular vesicles (ev) will be injected in patients diagnosed with knee osteoarthrosis

50 patients from both genders diagnosed with knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. these patients will be injected with extracellular vesicles (ev). then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (mri) of the injected knee.

Eligibility criteria:
inclusion criteria: * severe koa stage iii or iv by laurance \& kellgren staging as judged by posterioranterior (pa) xray of the knee joint. * willing to participate by signing the informed consent exclusion criteria: * sublaxation beyond 20 degrees of the bones of the knee joint * oral anticoagulants or heparin therapy * heart failure or arrhythmia * body mass index \> 35 * uncontrolled diabetes mellitus. * evidence of infectious diseases. * active infection * malignancy * pregnancy * anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000. * unreliable patients * non-resident in jordan

Keywords: osteoarthrosis knee extracellular vesicles
a study to investigate the pharmacokinetics of azd2389 when administered alone and in combination with itraconazole in healthy participants

Conditions: Healthy Participants

Summary: the purpose of this study is to assess the pharmacokinetics (pk) of azd2389 when administered alone and in combination with itraconazole in healthy participants.

this study will be an open-label, fixed sequence, drug-drug interaction (ddi) study consisting of 3 periods. the study will comprise: * a screening period of maximum 28 days * period 1 * period 2 * period 3 * a follow-up visit 7 to 14 days after the last pk sample has been collected.

Eligibility criteria:
inclusion criteria: * all females must have a negative pregnancy test at the screening visit and on admission to the clinical unit. * females of non-childbearing potential must be postmenopausal for at least 12 months or have documentation of irreversible surgical sterilization. * sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods. * have a body mass index (bmi) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg. exclusion criteria: * history of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * history or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * abnormal laboratory values, clinically important abnormalities or abnormal vital signs * any positive result on screening for serum hepatitis b surface antigen/antibody, hepatitis c, or human immunodeficiency virus. * current smokers (within 3 months prior to screening visit) or history of alcohol and drug abuse * history of severe allergy or hypersensitivity * excessive intake of caffeine-containing drinks or food * use of drugs with enzyme inducing properties or use of any prescribed or nonprescribed medication including antacids, analgesics

Keywords: fibroblast activation protein inhibitor advanced hepatic fibrosis chronic liver disease
comparison of dry needle and massotherapy on tolerance effort and soreness

Conditions: Delayed Onset Muscle Soreness

Summary: introduction: delayed onset muscle soreness (doms) is a common myogenic condition considered to be a muscle tension injury frequently observed in recreational or experienced athletes, induced in the majority of cases by eccentric and inactive exercises, the most common of which are: tension, pain and impairment muscular and have a course of typical duration of 24 hours and peak between 48 and 72 hours. among the treatments proposed with the aim of reducing the symptoms of doms is massage therapy. however, dry needling is a relatively new technique that has been used in myotendinous lesions and its effects on late muscle pain have not yet been studied. objective: to compare the impact of dry needling and massage therapy on exercise tolerance, and analgesia of sedentary individuals with late muscle pain induced by eccentric exercise. the present study is characterized as a randomized and blinded comparative study in which male sedentary individuals will be invited in which the late muscle pain will be induced through eccentric contractions and will receive different treatments: dry needling or massage therapy. the upper limb functionality, pain perception, superficial hyperemia and brachial biceps thickness will be compared through the exams: visual analogue pain scale (vas), digital algometry, thermography, ultrasonography and isometric test.


Eligibility criteria:
inclusion criteria: not practicing physical activity bmi greater than 18 and less than 30 members of the ufpe community exclusion criteria: making use of analgesic or anti-inflammatory medications acupuncture or dry needling or massage therapy in the last 6 months report of muscle pain orthopedic neurological problems hypertension and diabetes cardiovascular or respiratory diseases

Keywords: dry needling massotherapy delayed onset muscle soreness
impacts of intraperitoneal pressure and co2 gas on surgical peritoneal environment

Conditions: Laparoscopic Hysteretctomy With Promontofixation

Summary: use lay language. the primary purpose is to compare the impacts of intraperitoneal pressure (8mmhg versus 12 mmhg) and co2 gas (cool, dry co2 gas versus warmed, humidified co2 gas) on gene expression in peritoneal tissues during laparoscopic surgery. we hypothesize that combined use of a low intraperitoneal pressure (8mmhg) and warmed, humidified co2 gas during co2 pneumoperitoneum may be better in minimizing adverse effects on surgical peritoneal environment and improving clinical outcomes compared to the standard intraperitoneal pressure (12mmhg) and standard cool, dry co2 gas.

patients undergoing laparoscopic hysterectomy with promontofixation are randomized into four groups: group 1: 12mmhg intraperitoneal pressure with cool, dry co2 gas (n=20), group 2: 12mmhg intraperitoneal pressure with warmed, humidified co2 gas (n=20), group 3: 8mmhg intraperitoneal pressure with cool, dry co2 gas (n=20), group 4: 8mmhg intraperitoneal pressure with warmed, humidified co2 gas (n=20). normal peritoneum is collected from the parietal wall at the beginning of laparoscopic surgery and at 1 and 2 hours. expression of genes encoding components of the fibrinolytic system, extracellular matrix and adhesion molecules, and inflammatory cytokine signaling molecules in peritoneal tissues are measured by real-time pcr. quality of post-operative recovery by qor-40, post-operative pain by visual analog scale, per or post operative complications and intraoperative core temperature are assessed and compared.

Eligibility criteria:
inclusion criteria: * age 45-75 years old * petients undergoing laparoscopic hysterectomy with promontofixation for uterine prolapse * menopaused * asa class i or ii exclusion criteria: * absolute contraindications to laparoscopy * previous history of pelvic surgery, endometriosis and/or infection * pathological peritoneal tissue * bmi more than 30 * height less than 150cm

Keywords: carbon deoxide pneumoperitoneum intraperitoneal pressure peritoneum gene expression post-operative recovery laparoscopic humidification system
a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration

Conditions: Macular Degeneration

Summary: this is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * diagnosis of age-related macular degeneration in at least 1 eye * best corrected visual acuity of 20/40 to 20/320 in the study eye * best corrected visual acuity of 20/200 or better in the non-study eye exclusion criteria: * history of vitrectomy, macular surgery, or glaucoma surgery in the study eye * cataract or refractive surgery in the study eye within the last 3 months
iron deficiency anaemia in pregnant patients presenting for antenatal care

Conditions: Iron Deficiency Anemia of Pregnancy

Summary: this is a cross-sectional, prospective study of iron deficiency anaemia among pregnant patients presenting for antenatal care at a secondary level institution in the western cape, mowbray maternity hospital, over a one-week period.


Eligibility criteria:
inclusion criteria: * all women presenting to the antenatal care services at mowbray maternity hospital over the period of study recruitment. * ≥ 18 years of age. * screen as anaemic (world health organisation \<11g/dl) on bedside finger-prick haemoglobin. * who consent to participate. exclusion criteria: patients who refuse to participate, and those under the age of 18 years will be excluded from the study.
french cohort study of chronic heart failure patients with central sleep apnoea eligible for adaptive servo-ventilation (pacewave, autoset cs)

Conditions: Chronic Heart Failure; Central Sleep Apnea

Summary: the purpose of face study is to provide in routine practice complementary long-term data on the mortality and morbidity of chronic heart failure (chf) patients with central sleep apnea eligible for adaptative servo-ventilation (asv) treatment (pacewave, autoset cs; resmed).

the prevalence of central sleep apnea (csa) and/or cheyne-stokes respiration (csr) in patients with chronic heart failure (hf) is 15-46% and it is associated with worse prognosis. adaptative servo-ventilation (asv) suppresses sleep apnoea and reduces hyperventilation, and is more effective than continuous positive airway pressure (cpap) for treating csa/csr. short-term studies show that asv improves cardiac function and quality of life in chf patients. the serve hf multinational randomized trial is assessing the effects of addition of asv (pacewave, autoset cs; resmed) to optimal medical management compared with medical management alone in symptomatic chf patients with altered left ventricular ejection fraction and predominant csa/csr. the face study is a french prospective, multicentre, observational cohort that will provide complementary data to serve hf trial by characterizing chf population eligible for asv indications and evaluating the treatment management on long term follow-up of chf patients with csa/csr in routine practice.

Eligibility criteria:
inclusion criteria: * adult patient with chronic heart failure * central sleep apnea requiring asv therapy exclusion criteria: * contra-indications to asv therapy * respiratory failure or hypercapnia inconsistent with asv therapy

Keywords: congestive heart failure central sleep apnea sleep-disordered breathing
dietary and lifestyle interventions in obese pregnant women

Conditions: Obesity; Weight Gain; Lifestyle; Pregnancy Related

Summary: background: maternal obesity is associated with higher risks of adverse maternal and fetal complications, but the effects of dietary and lifestyle interventions on gestational weight gain(gwg) and pregnancy outcomes in obese pregnant women are unclear. objective: this study examined whether intensive dietary and lifestyle interventions initiated in the early pregnancy could decrease gwg, and prevent relevant adverse pregnancy outcomes in chinese obese pregnant women. design:a randomized controlled trial in obese pregnant women was performed at 6-12 weeks of gestation.the sample size was estimated using gwg reduction as the primary outcome variable. the investigators pilot study (data not published) showed the gestational weight gain was 12.73±5.97 for obese women. assuming intervention may result in 25% (3.1825g) reduction in gwg, the estimated sample size with 90% power and type i error of 0.05 was 114 women in intervention group and 57 in control group. adjusting for 15% refusal or loss to follow up during pregnancy, the total sample size required was 136 women in intervention group and 68 in control group(standard care group). participants were randomly assigned to the control or the intervention group. the intervention focused on restricting energy intake combined with behavioral lifestyle modification through participation in group sessions and individual counseling. the primary outcomes were gestational weight gain (gwg) and secondary outcomes were the incidence of gestational diabetes mellitus (gdm), hypertensive disorders during pregnancy, large-for-gestational-age (lga) infants, macrosomia and the rate of caesarian section. hypothesis:the intensive dietary and lifestyle intervention performed from the first trimester in obese women could decrease total gwg,and perhaps improve relevant pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * gestational age between 6 and 12 weeks of gestation, pre-pregnancy≥28 (kg/m2) * age ≥18 years, and a singleton pregnancy. exclusion criteria: * patients with prediabetes and diabetes, hypertension, chronic renal disease, thyroid disorder * gestational weeks ≥ 13 * age \<18 years * multiple pregnancy * uterine malformation * or physical restriction that prevents exercise.
effect of rosuvastatin on cytokines after traumatic brain injury

Conditions: Head Injury

Summary: the purpose of this study is to determine whether rosuvastatin could alter the immunological response after head injury by modulating tnf-alpha,il6,il-1.

the head injury is a frequent problem of health, which produces high morbid-mortality. today is the main cause of death and disability between 18 and 40 years. in addition it originates expensive expenses in health care systems. head injury produces damage by primary mechanisms related to impact, then by biochemical ways which are activated and they carry to secondary damage. many studies have been conducted for explaining secondary injury, the majority conclude there is a kind of ischemic lesion related maybe with changes in cerebral flow and metabolism. all these changes are associated to a immunological response. up to now some drugs are directed to modulate the immunological system, although many of them have been ineffective. statins o inhibitors of hmg coa reductase are drugs used in dyslipidemia, frequently for reduction in ldl. experimental and clinical studies in stroke have shown improvement in outcome. the toxicity related to statin is myopathy and hepatopathy, both with low incidence without fatal cases. rosuvastatin has been postulated be the most powerful with longest life and toxicity similar to another statins. many studies have suggested an important immunomodulator effect after statins administration, the investigators have previously demonstrated the possible effect of statin on amnesia and disorientation improvement with patients who suffered a moderated head injury (glasgow 9-13). the aim of this new study is to analyze the possible immunomodulator role of statins on head injury.

Eligibility criteria:
inclusion criteria: * man or woman \> 16 and \< 60 years old with hi less 24 hours in progression and glasgow between \< 13 * acceptance of family to participate (first grade) exclusion criteria: * previous head injury with severe disability * history of neurological or psychiatric disease with severe disability * administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone * very poor possibilities for survival * use of administration of tham, mannitol, barbiturates, corticosteroids, scavengers of free radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist, antagonists of neurotransmitters before randomization * isolated lesions in brain stem * allergy to the drug * hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease * management previous in other hospital * pregnancy

Keywords: moderate head injury rosuvastatin statin amnesia orientation
fundamental movement skills, body mass index and quality of life in children

Conditions: Overweight Children

Summary: early childhood obesity is a serious worldwide problem, and fundamental movement skills (fms) are very important factors in human movement. thus, several advanced studies have examined the associations between fms, body mass index (bmi) and quality of life. the purpose of this study was to investigate the relation between fms, bmi and quality of life in egyptian school aged children.

a total of 216 primary school aged children, aged 5-7 y from both sex participated in this study. fms were measured using the test of gross motor development-ii (tgmd-ii), and bmi was calculated as the weight (kg) divided by the square of the height (m) \[weight/ height2\] ,and quality of life was measured by pedsqol scale

Eligibility criteria:
inclusion criteria: - normal school aged children , aged 5-7 years with different weight categories exclusion criteria: * children with visual or auditory problems or those who experienced surgery in their lower limbs 1 year before study